A circRNA signature predicts postoperative recurrence in stage II/III colon cancer
Abstract Accurate risk stratification for patients with stage II/III colon cancer is pivotal for postoperative treatment decisions. Here, we aimed to identify and validate a circRNA‐based signature that could improve postoperative prognostic stratification for these patients. In current retrospectiv...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-09-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201810168 |
| _version_ | 1827015158252175360 |
|---|---|
| author | Huai‐Qiang Ju Qi Zhao Feng Wang Ping Lan Zixian Wang Zhi‐Xiang Zuo Qi‐Nian Wu Xin‐Juan Fan Hai‐Yu Mo Li Chen Ting Li Chao Ren Xiang‐Bo Wan Gong Chen Yu‐Hong Li Wei‐Hua Jia Rui‐Hua Xu |
| author_facet | Huai‐Qiang Ju Qi Zhao Feng Wang Ping Lan Zixian Wang Zhi‐Xiang Zuo Qi‐Nian Wu Xin‐Juan Fan Hai‐Yu Mo Li Chen Ting Li Chao Ren Xiang‐Bo Wan Gong Chen Yu‐Hong Li Wei‐Hua Jia Rui‐Hua Xu |
| author_sort | Huai‐Qiang Ju |
| collection | DOAJ |
| description | Abstract Accurate risk stratification for patients with stage II/III colon cancer is pivotal for postoperative treatment decisions. Here, we aimed to identify and validate a circRNA‐based signature that could improve postoperative prognostic stratification for these patients. In current retrospective analysis, we included 667 patients with R0 resected stage II/III colon cancer. Using RNA‐seq analysis of 20 paired frozen tissues collected postoperation, we profiled differential circRNA expression between patients with and without recurrence, followed by quantitative validation. With clinical information, we generated a four‐circRNA‐based cirScore to classify patients into high‐risk and low‐risk groups in the training cohort. The patients with high cirScores in the training cohort had a shorter disease‐free survival (DFS) and overall survival (OS) than patients with low cirScores. The prognostic capacity of the classifier was validated in the internal and external cohorts. Loss‐of‐function assays indicated that the selected circRNAs played functional roles in colon cancer progression. Overall, our four‐circRNA‐based classifier is a reliable prognostic tool for postoperative disease recurrence in patients with stage II/III colon cancer. |
| first_indexed | 2024-03-07T17:39:10Z |
| format | Article |
| id | doaj.art-94e8fd3a10b94556b180eefd64ab1aa9 |
| institution | Directory Open Access Journal |
| issn | 1757-4676 1757-4684 |
| language | English |
| last_indexed | 2025-02-18T14:18:05Z |
| publishDate | 2019-09-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj.art-94e8fd3a10b94556b180eefd64ab1aa92024-10-28T08:57:58ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842019-09-01111011310.15252/emmm.201810168A circRNA signature predicts postoperative recurrence in stage II/III colon cancerHuai‐Qiang Ju0Qi Zhao1Feng Wang2Ping Lan3Zixian Wang4Zhi‐Xiang Zuo5Qi‐Nian Wu6Xin‐Juan Fan7Hai‐Yu Mo8Li Chen9Ting Li10Chao Ren11Xiang‐Bo Wan12Gong Chen13Yu‐Hong Li14Wei‐Hua Jia15Rui‐Hua Xu16State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterThe Sixth Affiliated Hospital, Sun Yat‐sen UniversityState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterThe Sixth Affiliated Hospital, Sun Yat‐sen UniversityState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat‐sen UniversityState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterThe Sixth Affiliated Hospital, Sun Yat‐sen UniversityState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‐sen University Cancer CenterAbstract Accurate risk stratification for patients with stage II/III colon cancer is pivotal for postoperative treatment decisions. Here, we aimed to identify and validate a circRNA‐based signature that could improve postoperative prognostic stratification for these patients. In current retrospective analysis, we included 667 patients with R0 resected stage II/III colon cancer. Using RNA‐seq analysis of 20 paired frozen tissues collected postoperation, we profiled differential circRNA expression between patients with and without recurrence, followed by quantitative validation. With clinical information, we generated a four‐circRNA‐based cirScore to classify patients into high‐risk and low‐risk groups in the training cohort. The patients with high cirScores in the training cohort had a shorter disease‐free survival (DFS) and overall survival (OS) than patients with low cirScores. The prognostic capacity of the classifier was validated in the internal and external cohorts. Loss‐of‐function assays indicated that the selected circRNAs played functional roles in colon cancer progression. Overall, our four‐circRNA‐based classifier is a reliable prognostic tool for postoperative disease recurrence in patients with stage II/III colon cancer.https://doi.org/10.15252/emmm.201810168biomarkercircular RNArecurrencestage II/III colon cancer |
| spellingShingle | Huai‐Qiang Ju Qi Zhao Feng Wang Ping Lan Zixian Wang Zhi‐Xiang Zuo Qi‐Nian Wu Xin‐Juan Fan Hai‐Yu Mo Li Chen Ting Li Chao Ren Xiang‐Bo Wan Gong Chen Yu‐Hong Li Wei‐Hua Jia Rui‐Hua Xu A circRNA signature predicts postoperative recurrence in stage II/III colon cancer EMBO Molecular Medicine biomarker circular RNA recurrence stage II/III colon cancer |
| title | A circRNA signature predicts postoperative recurrence in stage II/III colon cancer |
| title_full | A circRNA signature predicts postoperative recurrence in stage II/III colon cancer |
| title_fullStr | A circRNA signature predicts postoperative recurrence in stage II/III colon cancer |
| title_full_unstemmed | A circRNA signature predicts postoperative recurrence in stage II/III colon cancer |
| title_short | A circRNA signature predicts postoperative recurrence in stage II/III colon cancer |
| title_sort | circrna signature predicts postoperative recurrence in stage ii iii colon cancer |
| topic | biomarker circular RNA recurrence stage II/III colon cancer |
| url | https://doi.org/10.15252/emmm.201810168 |
| work_keys_str_mv | AT huaiqiangju acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT qizhao acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT fengwang acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT pinglan acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT zixianwang acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT zhixiangzuo acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT qinianwu acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT xinjuanfan acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT haiyumo acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT lichen acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT tingli acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT chaoren acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT xiangbowan acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT gongchen acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT yuhongli acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT weihuajia acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT ruihuaxu acircrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT huaiqiangju circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT qizhao circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT fengwang circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT pinglan circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT zixianwang circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT zhixiangzuo circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT qinianwu circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT xinjuanfan circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT haiyumo circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT lichen circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT tingli circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT chaoren circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT xiangbowan circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT gongchen circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT yuhongli circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT weihuajia circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer AT ruihuaxu circrnasignaturepredictspostoperativerecurrenceinstageiiiiicoloncancer |